Tvardi Therapeutics, Inc. Common Stock TVRD
Analyst Ratings
- Consensus
- Moderate Buy — 4 Buy · 1 Hold · 1 Sell (6 analysts)
- Avg. Price Target
- $7.33 (+349.9% upside)
Key Stats
- Today's Range
- $1.59 – $1.66
- 50-Day Range
- $1.59 – $3.88
- 52-Week Range
- $1.50 – $43.65
- Volume
- 122K shs
- Average Volume
- 146K shs
- Market Cap
- $21.74 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.07%
- Days to Cover
- 1.00
About Tvardi Therapeutics, Inc. Common Stock
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Related Stocks
Compare head-to-head: TVRD vs LLY·TVRD vs JNJ·TVRD vs ABBV·TVRD vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.